Attached files
file | filename |
---|---|
EX-99.1 - PRESS RELEASE - TENAX THERAPEUTICS, INC. | oxbt_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 28, 2012
Oxygen Biotherapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware
|
001-34600
|
26-2593535
|
||
(State or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
ONE Copley Parkway, Suite 490
Morrisville, NC 27560
(Address of principal executive offices) (Zip Code)
919-855-2100
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
£
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
£
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
£
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
£
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01 Other Events.
On August 28, 2012, Oxygen Biotherapeutics, Inc., issued a press release regarding the relocation of its research and development activities from California to North Carolina and the concurrent subleasing of its California facilities, a copy of which is attached hereto as Exhibit 99.1.
Item 9.01
|
Financial Statements and Exhibits.
|
Exhibits
Attached to this report as Exhibit 99.1 is the “Press Release” dated August 28, 2012, identified in Item 8.01, above.
Exhibit No.
|
Description
|
99.1
|
Press release dated August 28, 2012
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 28, 2012
|
Oxygen Biotherapeutics, Inc.
|
|
By: /s/ Michael Jebsen
|
||
Michael Jebsen
|
||
President & Chief Financial Officer
|
EXHIBIT INDEX
Exhibit No.
|
Description
|
99.1
|
Press release dated August 28, 2012
|